Preliminary reports suggest interim positron emission tomography (PET) could drive treatment duration in limited-stage diffuse large B-cell lymphoma (DLBCL). This phase 3 randomised study in front-line therapy for DLBCL patients with adjusted-age IPI (aaIPI) risk = 0, evaluates an experimental PET-response adapted approach using PET response after 2 cycles of R-CHOP to de-escalate treatment duration.
Early Positron Emission Tomography Response-Adapted Treatment in Low-Risk Diffuse Large B-Cell lymphoma: an open label, multicenter, randomised, non-inferiority phase 3 trial.
Annals of Oncology | | Jean-Marie Michot, Serge Bologna, Jean-Noël Bastie, Thierry Vander Borght, Josette Brière, Vincent Ribrag, Come Bommier, Frédéric Peyrade, Laure Lebras, Gandhi Damaj, Diane Coso, David Sibon, Christophe Bonnet, Franck Morschhauser, Hervé Ghesquières, Christophe Fruchart, Carole Soussain, Stéphanie Becker, Pierre Olivier, Anne Julian, Thierry Molina, Corinne Haioun, Hervé Tilly
Topics: blood-cancer, clinical-trials, research